1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Instruments & Supplies
West Pharmaceutical Services, Inc.

West Pharmaceutical Services, Inc.

WST
West Pharmaceutical Services, Inc.US flagNew York Stock Exchange
342.73
USD
+0.10
- -
24.12BMarket Cap
West Pharmaceutical Services, Inc.
WST
(New York Stock Exchange)

Recent

price

342.73

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
16.59
17.69
18.62
19.66
20.05
19.44
20.59
21.64
23.24
24.86
29.05
38.06
38.8
39.7
39.63
42.52
46.32
Revenue per Share
0.98
1.12
1.19
1.61
1.79
1.33
1.96
2.04
2.8
3.27
4.68
8.9
7.88
7.99
6.75
6.83
7.86
Basic EPS, GAAP
2.04
1.92
2.75
3.11
2.58
2.95
2.99
3.56
3.91
4.96
6.39
7.85
9.73
10.45
8.95
10.44
9.22
Free Cash Flow per Basic Share
0.33
0.34
0.37
0.38
0.41
0.45
0.49
0.53
0.57
0.61
0.65
0.69
0.73
0.77
0.81
0.85
0.87
Dividend per Share
9.39
9.72
10.63
12.91
13.42
14.16
15.29
17.32
18.84
21.23
25.06
31.47
36.23
39.2
37.1
44.08
42.47
Book Value per Share
6.88
7.29
8.25
10.6
11.31
12.2
13.56
15.57
17.14
19.37
23.15
29.68
34.54
37.52
35.48
42.45
40.84
Tangible Book Value per Share
67
67
68
70
71
72
73
74
74
74
74
74
74
74
73
72
72
Basic Weighted Avg Shares
1,105
1,192
1,266
1,368
1,421
1,400
1,509
1,599
1,717
1,840
2,147
2,832
2,887
2,950
2,893
3,074
3,327
Sales/Revenue/Turnover
9.64
9.99
10.77
11.83
12.71
12.7
14.91
14.25
14.1
16.24
19.51
26.85
26.35
23.98
20.42
20.69
21.72
Operating Margin (%)
73
76
77
85
90
90
91
97
104
103
109
122
121
137
155
171
181
Depreciation Expense
65
76
81
112
127
96
144
151
207
242
346
662
586
593
493
494
565
Net Income, GAAP
18.26
25.35
30.11
27.33
27.93
22.65
28.66
36.38
17.2
20.22
18.07
14.31
16.87
17.52
18.36
20.24
20.79
Effective Tax Rate (%)
5.91
6.33
6.37
8.21
8.94
6.83
9.52
9.42
12.05
13.14
16.13
23.37
20.3
20.12
17.03
16.06
16.98
Profit Margin (%)
267
229
296
414
407
359
401
464
611
717
870
1,148
1,400
1,265
988
1,323
1,167
Working Capital
358
299
379
371
308
229
226
197
196
317
313
272
300
157
284
298
291
LT Debt
626
655
729
906
957
1,024
1,118
1,280
1,396
1,573
1,854
2,335
2,685
2,881
2,682
3,176
2,990
Total Equity
8.83
8.8
8.72
9.57
10.01
10.41
11.95
10.23
12.99
13.54
16.6
26.48
22.02
18.62
15.43
15.43
17.27
Return on Invested Capital (%)
8.14
8.96
8.61
10.3
10.81
8.15
11.2
11.03
13.94
14.22
17.29
27.63
20.92
19.4
16.04
15.25
17.4
Return on Capital (%)
10.84
11.79
11.66
13.73
13.64
9.65
13.41
12.57
15.46
16.28
20.2
31.59
23.34
21.32
17.71
16.85
19.09
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
23
21
21
LT Borrowings
203
203
203
LT Finance Leases
96
92
88
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
72
71
70
Market Capitalization
19,822
17,770
25,274

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,978
1,827
1,808
Cash, Cash Equivalents & STI
791
521
436
Accounts Receivable, Net
574
686
712
Inventories
444
453
447
Total Current Liabilities
655
674
640
Payables & Accruals
511
450
448
ST Debt
23
21
21
Deferred Revenue
52
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.3%
11.94%
18.41%
Free Cash Flow
14.33%
10.9%
15.52%
Net Income, GAAP
21.67%
12.84%
0.2%
Sales/Revenue/Turnover
8.53%
8.07%
6.25%
Total Cash Common Dividend
6.59%
4.94%
3.55%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
695
702
747
749
2,893
2025
698
766
805
805
3,074
2026
845
872
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.57
1.52
1.87
1.79
6.75
2025
1.24
1.83
1.94
1.83
6.83
2026
1.93
2.18
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.2
0.2
0.2
0.21
0.81
2025
0.21
0.21
0.21
0.22
0.85
2026
0.22
0.22
- -
- -
- -
Similar Companies
Platz Co., Ltd. (7813.T)
Paradigm Medical Industries, Inc. (PDMI)
Signature Eyewear, Inc. (SEYE)
Akoya Biosciences, Inc. (AKYA)
Advanced Medical Solutions Group plc (AMS.L)
AtriCure, Inc. (ATRC)
Business
West Pharmaceutical Services, Inc. is a global manufacturer and provider of integrated containment and delivery systems primarily for injectable drugs and healthcare products. The company's core offerings include stoppers and seals for injectable packaging systems; syringe and cartridge components; self-injection devices featuring patient-centric, connected health technologies; and advanced containment and delivery solutions such as the proprietary Daikyo Crystal Zenith polymer, a high-performance glass alternative suited for sensitive biologics. West also provides contract manufacturing services encompassing injection molding, contract assembly, and finished packaging through facilities in North America and Europe. Founded in 1923, the company is headquartered in Exton, Pennsylvania, and serves pharmaceutical, biologics, vaccine, and consumer healthcare markets worldwide. Recent major strategic developments at West include the launch of the West Synchrony™ Prefillable Syringe System, an innovative, fully verified system-level product designed specifically for biologics and vaccines scheduled for commercial availability in 2026. This system integrates syringe barrel, plunger, and needle components into a harmonized platform that accelerates regulatory submission and enhances supply chain reliability. In addition, West has strengthened its collaboration with Corning Incorporated, combining West’s NovaPure components and Daikyo Flurotec coating technology with Corning’s Valor® Glass and Velocity® Vials to develop advanced pharmaceutical packaging solutions that improve patient safety and drug stability. Furthermore, West has made a strategic investment in Latch Medical, a Dublin-based company specializing in next-generation vaccine and biologics delivery technology focused on intradermal delivery. West operates across more than 50 sites worldwide, including 25 manufacturing locations, supporting its expansive global supply chain. The company reported $2.89 billion in net sales for fiscal year 2024 and is publicly traded on the New York Stock Exchange under the ticker WST. It is also included in the Standard & Poor’s 500 index, reflecting its prominence as a trusted partner to established and emerging drug developers for the safe containment and delivery of life-saving medicines on a global scale. This comprehensive integration of innovative product offerings and strategic partnerships underscores West Pharmaceutical Services’ position as a leader in injectable drug delivery systems, supported by a nearly century-long heritage of technological advancement and manufacturing excellence.

Company News

Company News APIChatGPT

  • defenseworld.net

    Benjamin Edwards Inc. Grows Position in West Pharmaceutical Services, Inc. $WST

  • defenseworld.net

    West Pharmaceutical Services, Inc. (NYSE:WST) Receives Average Recommendation of “Moderate Buy” from Brokerages

  • defenseworld.net

    7,730 Shares in West Pharmaceutical Services, Inc. $WST Bought by Caisse de depot et placement du Quebec

  • prnewswire.com

    West to Participate in Upcoming Investor Conferences

  • defenseworld.net

    3,700 Shares in West Pharmaceutical Services, Inc. $WST Purchased by Barbara Oil Co.

  • defenseworld.net

    Advisors Capital Management LLC Acquires New Shares in West Pharmaceutical Services, Inc. $WST

  • zacks.com

    WST Stock Surges 38.1% Since March-End: What's Fueling the Rally?

  • zacks.com

    West Pharmaceutical (WST) Upgraded to Buy: Here's Why

  • zacks.com

    Should Investors Buy WST as HVP Growth Meets a Premium Valuation?

  • zacks.com

    WST Q2 Beat and Raised 2026 Outlook Reinforce the HVP Growth Story

  • zacks.com

    WST Gains 15.3% in Three Months as HVP Growth Strengthens Outlook

  • seekingalpha.com

    Conestoga SMid Cap Composite Q2 2026 Portfolio Review

  • defenseworld.net

    West Pharmaceutical Services, Inc. $WST Holdings Increased by Dimensional Fund Advisors LP

  • defenseworld.net

    West Pharmaceutical Services, Inc. $WST Shares Acquired by Bank of Nova Scotia

  • seekingalpha.com

    West Pharmaceutical Delivers Another Beat - But The Real Story Is The Mix Shift

  • marketbeat.com

    West Pharmaceutical Services Q2 Earnings Call Highlights

  • zacks.com

    WST Stock Jumps on Q2 Earnings & Sales Beat, EPS View Up on HVP Growth

  • seekingalpha.com

    West Pharmaceutical Services, Inc. (WST) Q2 2026 Earnings Call Transcript

  • benzinga.com

    West Pharmaceutical CEO Highlights GLP-1 And Biologics Momentum

  • zacks.com

    West Pharmaceutical (WST) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates